author-photo

D Yee

University of Minnesota

40

Papers

617

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

2021 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (5)
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial

2020
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract S5-07: Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

2017
Show All
- Source
- Cite
- Save
Citations (49)
Abstract P2-11-02: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)